Orexo AB (STO:ORX) announces successful completion of the initial pharmacokinetic trial in the OX219 project. In the comparative bioavailability study, the OX219 buprenorphine/naloxone sublingual tablet formulation demonstrated favourable profiles compared to the comparator Suboxone®, which is the market leading product for treatment of opioid dependence. Global value of the opioid dependence market today is approximately US$ 1.4 billion. Based on the positive results, Orexo will be meeting with the FDA during Q1-2011 to discuss the development program for OX219… (Source: Health News from Medical News Today)

OPIOID-DEPENDENT PATIENTS present a unique perioperative care challenge. These patients are managed as outpatients in several different manners. The type of treatment that such patients receive can have a profound impact on their perioperative care when they present for surgery. One management option is the use of sublingual (SL) buprenorphine to treat opioid dependence. This drug is available as either Suboxone or Subutex (Reckitt Benckiser Pharmaceuticals, Inc, Richmond, VA). Subutex contains buprenorphine only, whereas Suboxone contains buprenorphine and naloxone to deter diversion to the injectable route (naloxone will precipitate opioid withdrawal if injected, but has no effect if taken sublingually or orally). As we shall see, the same properties that make buprenorphine effective in…

Conclusions: Our data indicates that the inhalation of buprenorphine has occurred in a significant minority of Australian OST clients. The motivations, contexts and potential health consequences of buprenorphine use by these atypical routes of administration, particularly in a correctional setting, warrant further exploration. (Source: International Journal of Drug Policy)

The state of New York plans to give some state prisoners the opiate-treatment drug Suboxone to help them stay off heroin upon release. (Source: Alcohol, Tobacco and Other Drugs News)

Conclusions: Accidental and non-accidental ingestion of methadone and buprenorphine by children is increasing in proportion to increased clinical use and availability. Health providers should be aware of this increased risk and be able to provide appropriate treatment and family support.
PMID: 21047302 [PubMed – as supplied by publisher] (Source: Current Drug Safety)

The Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Patients with Chronic, Non-Malignant Pain who are Maintained on Sublingual Buprenorphine/Naloxone

Neuropsychopharmacology advance online publication, October 27, 2010. doi:10.1038/npp.2010.172

Authors: Jermaine D Jones, Maria A Sullivan, Jeanne Manubay, Suzanne K Vosburg
& Sandra D Comer
Keywords: opioids; pain/analgesics; addiction & substance abuse; psychopharmacology; buprenorphine (Source: Neuropsychopharmacology)

Authors: Maremmani I, Gerra G
Maintenance therapy with methadone or buprenorphine-based regimens reduces opioid dependence and associated harms. The perception that methadone is more effective than buprenorphine for maintenance treatment has been based on low buprenorphine doses and excessively slow induction regimens used in early buprenorphine trials. Subsequent studies show that the efficacy of buprenorphine sublingual tablet (Subutex®) or buprenorphine/naloxone sublingual tablet (Suboxone®) is equivalent to that of methadone when sufficient buprenorphine doses, rapid induction, and flexible dosing are used. Although methadone remains an essential maintenance therapy option, buprenorphine-based regimens increase access to care and provide safer, more appropriate treatment than met…

(MedPage Today) — An implantable form of the opioid addiction drug buprenorphine (Subutex, Suboxone) kept more patients testing “clean” for four months compared with placebo, researchers reported. (Source: MedPage Today Psychiatry)

Conclusion  Among persons with opioid dependence, the use of buprenorphine implants compared with placebo resulted in less opioid use over 16 weeks as assessed by urine samples.
Trial Registration  clinicaltrials.gov Identifier: NCT00447564 (Source: JAMA)

Suboxone (Buprenorphine HCl and naloxone HCl) drug description – FDA approved labeling for prescription drugs and medications at RxList (Source: RxList – New and Updated Drug Monographs)